Maria Learoyd

1.4k citations

25 papers · 1.0k indexed · 1 hit paper · h-index 15

Impact in

Molecular Medicine top 5%
- Antibiotic Resistance in Bacteria
Applied Microbiology and Biotechnology top 5%

Papers in ⓘ

Oncology 16
- PARP inhibition in cancer therapy 12
- Colorectal Cancer Treatments and Studies 3
- HER2/EGFR in Cancer Research 3
Molecular Biology 7

Co-authors: Timi Edeki (5 shared papers)Shampa Das (3 shared papers)J. Armstrong (2 shared papers)James Li (2 shared papers)Darren Hodgson (1 shared paper)Robert H. Jones (1 shared paper)Aude Fléchon (1 shared paper)Noel W. Clarke (1 shared paper)
Journals: Clinical Pharmacology & Therapeutics (3 papers)Journal of Clinical Oncology (3 papers)Cancer Chemotherapy and Pharmacology (2 papers)Clinical Pharmacokinetics (2 papers)Journal of Antimicrobial Chemotherapy (1 paper)
Partner nations: United Kingdom United States Netherlands

In The Last Decade

Maria Learoyd

24 papers receiving 990 citations

Hit Papers

align trajectories log scale

Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial 2018 · 281 citations

Peers

Countries citing papers authored by Maria Learoyd

Since Specialization

Citations

This map shows the geographic impact of Maria Learoyd's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Maria Learoyd with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Maria Learoyd more than expected).

Fields of papers citing papers by Maria Learoyd

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Maria Learoyd. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Maria Learoyd. The network helps show where Maria Learoyd may publish in the future.

Co-authors

The 25 scholars most cited alongside Maria Learoyd, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Maria Learoyd Line = papers co-authored together Maria Learoyd links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 25 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial The Lancet Oncology ·Noel W. Clarke, Paweł Wiechno, B. Yа. Alekseev, Núria Sala, Robert H. Jones, Ivo Kocák, Vincenzo Emanuele Chiurì, Jacek Jassem, Aude Fléchon, Charles H. Redfern, Carsten Goessl, Joseph E. Burgents, Robert Kozarski, Darren Hodgson, Maria Learoyd, Fred Saad Hit paper breakdown →	2018	281
2	An open-label, phase II basket study of olaparib and durvalumab (MEDIOLA): Results in germline BRCA -mutated ( gBRCA m) platinum-sensitive relapsed (PSR) ovarian cancer (OC) Gynecologic Oncology ·Yvette Drew, Maja J.A. de Jonge, Sook Hee Hong, Y.H. Park, Anita Wolfer, Jennifer R. Brown, Michelle Ferguson, Martin Gore, Ricardo H. Álvarez, Christopher Gresty, Helen K. Angell, Kassondra Meyer, Maria Learoyd, Minhong Tang, Mark C. Lanasa, Pia Herbolsheimer, Susan M. Domchek	2018	111
3	Phase II Study of the Mitogen-Activated Protein Kinase 1/2 Inhibitor Selumetinib in Patients With Advanced Hepatocellular Carcinoma Journal of Clinical Oncology ·Bert H. O’Neil, Laura W. Goff, John Kauh, Jonathan Strosberg, Tanios Bekaii‐Saab, Ruey-min Lee, Aslamuzzaman Kazi, Dominic T. Moore, Maria Learoyd, Richard M. Lush, Saı̈d M. Sebti, Daniel M. Sullivan	2011	110
4	Phase 1 study assessing the steady-state concentration of ceftazidime and avibactam in plasma and epithelial lining fluid following two dosing regimens Journal of Antimicrobial Chemotherapy ·David P. Nicolau, Leonard Siew, J. Armstrong, James Li, Timi Edeki, Maria Learoyd, Shampa Das	2015	106
5	Physiologically Based Pharmacokinetic Modeling for Olaparib Dosing Recommendations: Bridging Formulations, Drug Interactions, and Patient Populations Clinical Pharmacology & Therapeutics ·Venkatesh Pilla Reddy, Khanh Bui, Graeme Scarfe, Diansong Zhou, Maria Learoyd	2018	47
6	Abstract PD6-11: An open-label, multitumor, phase II basket study of olaparib and durvalumab (MEDIOLA): Results in germline BRCA -mutated (g BRCA m) HER2-negative metastatic breast cancer (MBC) Cancer Research ·S. M. Domchek, Sophie Postel‐Vinay, Y-J. Bang, YH Park, Jérôme Alexandre, J.P. Delord, Antoîne Italiano, Benoît You, Susan E.P. Bastian, Matthew Krebs, Dawei Wang, Saiama N. Waqar, Helen K. Angell, Maria Learoyd, Shan‐Chwen Chang, Christopher Gresty, Pia Herbolsheimer, Bella Kaufman	2018	41
7	A phase I dose-finding, safety and tolerability study of AZD8330 in patients with advanced malignancies European Journal of Cancer ·Roger B. Cohen, Steinar Aamdal, Marta Nyakas, Maria Cavallin, Darron Green, Maria Learoyd, Ian C. P. Smith, Razelle Kurzrock	2013	40
8	A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors Cancer Chemotherapy and Pharmacology ·Suzanne Leijen, Patricia M.M.B. Soetekouw, T.R. Jeffry Evans, M. Nicolson, Jan H.M. Schellens, Maria Learoyd, Lynda Grinsted, Victoria Zazulina, Thinn Pwint, Mark R. Middleton	2011	37
9	Randomized pharmacokinetic and drug–drug interaction studies of ceftazidime, avibactam, and metronidazole in healthy subjects Pharmacology Research & Perspectives ·Shampa Das, Jianguo Li, J. Armstrong, Maria Learoyd, Timi Edeki	2015	34
10	Phase I study assessing the safety, tolerability, and pharmacokinetics of avibactam and ceftazidime–avibactam in healthy Japanese volunteers Journal of Infection and Chemotherapy ·N. Tominaga, Timi Edeki, James Li, Maria Learoyd, M. René Bouw, Shampa Das	2015	31
11	In vitro evaluation of the inhibition and induction potential of olaparib, a potent poly(ADP-ribose) polymerase inhibitor, on cytochrome P450 Xenobiotica ·Alex McCormick, Helen Swaisland, Venkatesh Pilla Reddy, Maria Learoyd, Graeme Scarfe	2017	26
12	Bridging Olaparib Capsule and Tablet Formulations Using Population Pharmacokinetic Meta-analysis in Oncology Patients Clinical Pharmacokinetics ·Diansong Zhou, Jianguo Li, Khanh Bui, Maria Learoyd, Aliénor Berges, Tsveta Milenkova, Nidal Al‐Huniti, Helen Tomkinson, Hongmei Xu	2018	25
13	Pharmacokinetics and Safety of Olaparib in Patients with Advanced Solid Tumours and Renal Impairment Clinical Pharmacokinetics ·Christian Rolfo, Judith de Vos‐Geelen, Nicolás Isambert, L. Rhoda Molife, Jan H.M. Schellens, Jacques De Grève, Luc Dirix, Peter Grundtvig-Sørensen, Guy Jérusalem, Karin Leunen, Morten Mau‐Sørensen, Ruth Plummer, Maria Learoyd, Wendy Bannister, Anitra Fielding, Alain Ravaud	2019	23
14	Phase I, dose-finding study of AZD8931, an inhibitor of EGFR (erbB1), HER2 (erbB2) and HER3 (erbB3) signaling, in patients with advanced solid tumors Investigational New Drugs ·S. Tjulandin, Vladimir Moiseyenko, В. В. Семиглазов, George Manikhas, Maria Learoyd, A. Saunders, Melissa K. Stuart, Ulrich Keilholz	2013	21
15	Efficacy and Safety Exposure‐Response Analyses of Olaparib Capsule and Tablet Formulations in Oncology Patients Clinical Pharmacology & Therapeutics ·Diansong Zhou, Jianguo Li, Maria Learoyd, Khanh Bui, Aliénor Berges, Tsveta Milenkova, Nidal Al‐Huniti, Helen Tomkinson, Hongmei Xu	2018	16
16	Pharmacokinetics and safety of olaparib in patients with advanced solid tumours and mild or moderate hepatic impairment British Journal of Clinical Pharmacology ·Christian Rolfo, Nicolás Isambert, Antoîne Italiano, L. Rhoda Molife, Jan H.M. Schellens, Jean‐Yves Blay, Thomas Decaens, Rebecca Kristeleit, Olivier Rosmorduc, Regina Demlová, M.A. Lee, Alain Ravaud, Kateřina Kopečková, Maria Learoyd, Wendy Bannister, Gershon Y. Locker, Judith de Vos‐Geelen	2020	14
17	A Randomized, Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of Ceftazidime-Avibactam in Healthy Chinese Subjects Clinical Drug Investigation ·Jianguo Li, Maria Learoyd, Furong Qiu, Leilei Zhu, Timi Edeki	2015	11
18	Pharmacokinetic Effects and Safety of Olaparib Administered with Endocrine Therapy: A Phase I Study in Patients with Advanced Solid Tumours Advances in Therapy ·Ruth Plummer, Henk M.W. Verheul, Filip De Vos, Karin Leunen, L. Rhoda Molife, Christian Rolfo, Peter Grundtvig-Sørensen, Jacques De Grève, Sylvie Rottey, Guy Jérusalem, Antoîne Italiano, James Spicer, Luc Dirix, Carsten Goessl, Joseph Birkett, Stuart Spencer, Maria Learoyd, Christopher J. Bailey, Emma Dean	2018	10
19	Pharmacokinetics and safety of olaparib tablets as monotherapy and in combination with paclitaxel: results of a Phase I study in Chinese patients with advanced solid tumours Cancer Chemotherapy and Pharmacology ·Peng Yuan, Jianzhong Shentu, Jianming Xu, Wendy Burke, Kate Hsu, Maria Learoyd, Min Zhu, Binghe Xu	2019	7
20	An open-label, non-randomised, phase 1, single-dose study to assess the pharmacokinetics of ceftaroline in patients with end-stage renal disease requiring intermittent haemodialysis International Journal of Antimicrobial Agents ·Maria Sunzel, Maria Learoyd, Jianguo Li, Yan Li, Ngoc Ngo, Timi Edeki	2015	3

About Maria Learoyd

Maria Learoyd is a scholar working on Oncology, Molecular Biology, Pharmacology, Epidemiology and Pulmonary and Respiratory Medicine, having authored 25 papers that have together received 1.0k indexed citations. Recurring topics across this work include PARP inhibition in cancer therapy (12 papers), Antibiotics Pharmacokinetics and Efficacy (5 papers), Antibiotic Resistance in Bacteria (4 papers), Pneumonia and Respiratory Infections (4 papers), Colorectal Cancer Treatments and Studies (3 papers), Toxin Mechanisms and Immunotoxins (3 papers), HER2/EGFR in Cancer Research (3 papers) and Ovarian cancer diagnosis and treatment (3 papers). The work is most often cited by research in Molecular Medicine (163 citations), Applied Microbiology and Biotechnology (51 citations), Oncology (559 citations), Reproductive Medicine (93 citations) and Pharmacology (159 citations). Maria Learoyd has collaborated with scholars based in United Kingdom, United States and Netherlands. Frequent co-authors include Timi Edeki, Shampa Das, J. Armstrong, James Li, Darren Hodgson, Robert H. Jones, Aude Fléchon, Noel W. Clarke, Paweł Wiechno and B. Yа. Alekseev. Their work appears in journals such as Clinical Pharmacology & Therapeutics, Journal of Clinical Oncology, Cancer Chemotherapy and Pharmacology, Clinical Pharmacokinetics and Journal of Antimicrobial Chemotherapy.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact